Tags

Type your tag names separated by a space and hit enter

Antiagalactosyl IgG antibodies in juvenile idiopathic arthritis, juvenile onset Sjögren's syndrome, and healthy children.
J Rheumatol. 2004 Jun; 31(6):1211-7.JR

Abstract

OBJECTIVE

To determine the normal range of antiagalactosyl IgG antibodies in healthy children, and to investigate the utility of determination of antiagalactosyl IgG antibodies in patients with juvenile idiopathic arthritis (JIA) and juvenile onset Sjögren's syndrome (SS).

METHODS

Serum concentrations of antiagalactosyl IgG antibodies were measured in 225 healthy children, 68 patients with JIA (systemic arthritis in 21, polyarthritis in 29, oligoarthritis in 18), and 15 patients with juvenile onset SS, using a lectin-enzyme immunoassay employing prepared human agalactosyl IgG as antigen. A comparison was made between the prevalence and utility of antiagalactosyl IgG antibodies in patients and those of conventional rheumatoid factors (RF) determined by laser nephelometry.

RESULTS

The average serum concentration of antiagalactosyl IgG antibodies for healthy controls was 2.41 +/- 0.93 arbitrary units (AU)/ml, and the cutoff value of the normal range was set at 4.3 AU/ml (mean + 2 SD). As a result, antiagalactosyl IgG antibodies were positive in 25 (37%) of 68 patients with JIA, and 14 (93%) of 15 patients with juvenile onset SS, in whom values were much higher than the frequencies of RF positivity. The serum concentrations of antiagalactosyl IgG antibodies in patients were closely correlated with those of RF. Thirteen patients with JIA and 6 patients with juvenile onset SS were positive for antiagalactosyl IgG antibodies despite being negative for RF. With regard to prognosis during followup periods of at least 5 years, JIA patients positive for antiagalactosyl IgG antibodies, even if negative for RF, were resistant to treatment. However, positivity for antiagalactosyl IgG antibodies had no relation to joint destruction.

CONCLUSION

Our data suggest that antiagalactosyl IgG antibodies, compared with RF, show higher sensitivity to detect immunological disorders in JIA and juvenile onset SS.

Authors+Show Affiliations

Department of Bacteriology and the Department of Pediatrics, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15170938

Citation

Maeno, Nobuaki, et al. "Antiagalactosyl IgG Antibodies in Juvenile Idiopathic Arthritis, Juvenile Onset Sjögren's Syndrome, and Healthy Children." The Journal of Rheumatology, vol. 31, no. 6, 2004, pp. 1211-7.
Maeno N, Takei S, Fujikawa S, et al. Antiagalactosyl IgG antibodies in juvenile idiopathic arthritis, juvenile onset Sjögren's syndrome, and healthy children. J Rheumatol. 2004;31(6):1211-7.
Maeno, N., Takei, S., Fujikawa, S., Yamada, Y., Imanaka, H., Hokonohara, M., Kawano, Y., & Oda, H. (2004). Antiagalactosyl IgG antibodies in juvenile idiopathic arthritis, juvenile onset Sjögren's syndrome, and healthy children. The Journal of Rheumatology, 31(6), 1211-7.
Maeno N, et al. Antiagalactosyl IgG Antibodies in Juvenile Idiopathic Arthritis, Juvenile Onset Sjögren's Syndrome, and Healthy Children. J Rheumatol. 2004;31(6):1211-7. PubMed PMID: 15170938.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiagalactosyl IgG antibodies in juvenile idiopathic arthritis, juvenile onset Sjögren's syndrome, and healthy children. AU - Maeno,Nobuaki, AU - Takei,Syuji, AU - Fujikawa,Satoshi, AU - Yamada,Yuji, AU - Imanaka,Hiroyuki, AU - Hokonohara,Masashi, AU - Kawano,Yoshifumi, AU - Oda,Hiroshi, PY - 2004/6/2/pubmed PY - 2004/9/15/medline PY - 2004/6/2/entrez SP - 1211 EP - 7 JF - The Journal of rheumatology JO - J. Rheumatol. VL - 31 IS - 6 N2 - OBJECTIVE: To determine the normal range of antiagalactosyl IgG antibodies in healthy children, and to investigate the utility of determination of antiagalactosyl IgG antibodies in patients with juvenile idiopathic arthritis (JIA) and juvenile onset Sjögren's syndrome (SS). METHODS: Serum concentrations of antiagalactosyl IgG antibodies were measured in 225 healthy children, 68 patients with JIA (systemic arthritis in 21, polyarthritis in 29, oligoarthritis in 18), and 15 patients with juvenile onset SS, using a lectin-enzyme immunoassay employing prepared human agalactosyl IgG as antigen. A comparison was made between the prevalence and utility of antiagalactosyl IgG antibodies in patients and those of conventional rheumatoid factors (RF) determined by laser nephelometry. RESULTS: The average serum concentration of antiagalactosyl IgG antibodies for healthy controls was 2.41 +/- 0.93 arbitrary units (AU)/ml, and the cutoff value of the normal range was set at 4.3 AU/ml (mean + 2 SD). As a result, antiagalactosyl IgG antibodies were positive in 25 (37%) of 68 patients with JIA, and 14 (93%) of 15 patients with juvenile onset SS, in whom values were much higher than the frequencies of RF positivity. The serum concentrations of antiagalactosyl IgG antibodies in patients were closely correlated with those of RF. Thirteen patients with JIA and 6 patients with juvenile onset SS were positive for antiagalactosyl IgG antibodies despite being negative for RF. With regard to prognosis during followup periods of at least 5 years, JIA patients positive for antiagalactosyl IgG antibodies, even if negative for RF, were resistant to treatment. However, positivity for antiagalactosyl IgG antibodies had no relation to joint destruction. CONCLUSION: Our data suggest that antiagalactosyl IgG antibodies, compared with RF, show higher sensitivity to detect immunological disorders in JIA and juvenile onset SS. SN - 0315-162X UR - https://www.unboundmedicine.com/medline/citation/15170938/Antiagalactosyl_IgG_antibodies_in_juvenile_idiopathic_arthritis_juvenile_onset_Sjögren's_syndrome_and_healthy_children_ L2 - http://www.jrheum.org/cgi/pmidlookup?view=long&pmid=15170938 DB - PRIME DP - Unbound Medicine ER -